Enanta Pharma (ENTA) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Enanta Pharma (ENTA) Falls 25% Despite "Positive" Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
May 8, 2023 4:56 PM EDTEnanta Pharma (NASDAQ: ENTA) Falls 25% Despite "Positive" Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
Study Met Primary Endpoints of Safety and TolerabilityDose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to... More